Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Imperial College London AstraZeneca |
---|---|
Information provided by: | Imperial College London |
ClinicalTrials.gov Identifier: | NCT00291408 |
The purpose of the study is to compare histone acetyltransferase (HAT) and histone deacetylase (HDAC) expressions and activities in induced sputum macrophages obtained from patients with moderate to severe COPD and age-matched normal non-smokers
Condition | Intervention | Phase |
---|---|---|
Chronic Obstructive Pulmonary Disease (COPD) Age Matched Healthy Volunteers (Non-Smokers) |
Procedure: Skin Prick Test Procedure: Impulse Oscillometry Procedure: Exhaled Nitric Oxide Procedure: Spirometry Procedure: Reversibility Procedure: Exhaled Breath Condensate Procedure: Sputum Induction |
Phase IV |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Pharmacokinetics Study |
Official Title: | A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Effect of Symbicort® and Pulmicort® on HAT and HDAC Expression and Activity in Induced Sputum Cells Obtained From COPD Patients. |
Estimated Enrollment: | 48 |
Study Start Date: | April 2006 |
Study Completion Date: | June 2007 |
Primary Completion Date: | June 2007 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 40 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Inclusion Criteria-Healthy non-smokers
Inclusion Criteria-COPD patients (stage II-III according to the GOLD guidelines)
Exclusion Criteria:
Exclusion Criteria-Healthy non-smokers
Exclusion Criteria-COPD patients
United Kingdom | |
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital | |
London, United Kingdom, SW3 6LY |
Principal Investigator: | Peter J Barnes, MA DM DSc FRCP | Imperial College London |
Principal Investigator: | Kazuhiro Ito, PhD | Imperial College London |
Principal Investigator: | Ian Adcock, PhD | Imperial College London |
Principal Investigator: | Sergei A Kharitonov, MD PhD | Imperial College London |
Study ID Numbers: | 05/Q0403/171, EudraCT Number: 2005-003297-13 |
Study First Received: | February 13, 2006 |
Last Updated: | April 4, 2008 |
ClinicalTrials.gov Identifier: | NCT00291408 |
Health Authority: | United Kingdom: Research Ethics Committee |
Nitric Oxide Lung Diseases, Obstructive Symbicort Respiratory Tract Diseases |
Lung Diseases Budesonide Healthy Pulmonary Disease, Chronic Obstructive |
Respiratory System Agents Vasodilator Agents Neurotransmitter Agents Antioxidants Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Anti-Asthmatic Agents Cardiovascular Agents |
Protective Agents Pharmacologic Actions Autonomic Agents Therapeutic Uses Free Radical Scavengers Endothelium-Dependent Relaxing Factors Peripheral Nervous System Agents Bronchodilator Agents |